Willisriise6151

2-87.1, respectively; P less then 0.05 for both). Conclusion OS is associated with sarcopenia in COPD.Introduction There is growing awareness of the importance of patient centered care (PCC) in health care. Within Radiography in the UK, elements of PCC are embedded within professional body publications and guidance documents. However, there is limited research evidence exploring whether perceptions of PCC are equivalent between those delivering (radiographers) and those experiencing (patient) care. This study aimed to address this gap by determining compatibility in perceptions of PCC between those using and those delivering radiography services. This is the first step in developing measurable indicators of PCC in diagnostic radiography. Methods A multi-method two stage approach was undertaken using survey and interview data collection techniques. Ethical approval was granted by University of Derby College of Health & Social Care Ethics committee. This paper reports Stage 1 of the study, the online, cross sectional survey. Participants were asked to indicate their level of agreement to a series of attitudinal statements using a 5-point Likert scale. Statements were paired, but not co-located to increase validity. Participants were invited to provide free text comments to supplement their responses. Stage 2 of the project is reported separately. Results Survey responses were received from all 3 participant subgroups. selleck products A minimum response rate of 30 participants per sub-group was set as a target. Response rates varied across subgroups, with only radiography managers failing to meet the expected response threshold. Wide disparity between perceptions of service users and those delivering radiography services on what constitutes high quality PCC was evident. Conclusion It is evident that there is still work required to ensure parity between expectations of service users and deliverers on what constitutes high quality PCC. Implications for practice Further work is required to identify measurable service delivery outcomes that represent PCC within radiographic practice.Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of cardiovascular events, a varying burden of symptoms, and an intrinsic risk of evolution to secondary forms of myelofibrosis and acute leukemia; however, survival is only modestly reduced in most instances. In the last few years, following the description of driver mutations in JAK2, MPL and CALR, the diagnostic criteria for PV and ET were revised, making the identification of very early stages feasible. Scores for identifying patients at different risk of thrombosis were refined, and they largely guide therapeutic decisions. Treatment is therefore mainly focused on reduction of thrombosis risk, control of myeloproliferation, improvement of symptomatic burden, and management of disease-associated complications. New drugs recently entered the clinical arena, with the promise to improve overall patients' management. However, evidence of a disease-modifying potential is largely missing and represents a still unmet clinical need.We performed a dosimetric study to evaluate the benefits of using a flattening-filter-free (FFF) beam with the deep inspiration breath-hold (DIBH) method for left-breast cancer. We used data from 30 previous patients with treatment plans that included DIBH for left-breast cancer with a flattened beam. FFF beam plans were calculated from previous treatment plan images and compared to the original plans in terms of monitor units (MU), number of segments, beam-on time, and breath-holds. Beam-on time was calculated by adding the traveling time of 1.5 second between segments to the time calculated from the MU and dose rate. Breath-holds were calculated based on the beam-on time, assuming 15 s per hold. The FFF beam had increased MU in all cases (mean ± SD flattened beam, 122.4 ± 9.8 MU; FFF beam, 160.2 ± 17.5 MU). Furthermore, the number of segments increased with the FFF beam in all cases (median [range] flattened beam, 2 [1 to 3]; FFF beam, 5 [3 to 7]). However, in most cases, the beam-on time was reduced using the FFF beam (mean ± SD flattened beam, 27.8 ± 7.4 seconds; FFF beam, 13.2 ± 1.7 seconds), although when a 6 MV flattened beam was used there was not a large increase. There were fewer breath-holds in most cases with the FFF beam. Cases using a 4 MV flattened beam also had fewer breath-holds; however, the number of breath-holds was consistent or increased in cases that used a 6 MV flattened beam (median [range] flattened beam, 3 [1 to 3]; FFF beam, 1 [1 to 2]).Cognitive impairments constitute a core feature of schizophrenia, and a genetic overlap between schizophrenia and cognitive functioning in healthy individuals has been identified. However, due to the high polygenicity and complex genetic architecture of both traits, overlapping biological pathways have not yet been identified between schizophrenia and normal cognitive ability. Network medicine offers a framework to study underlying biological pathways through protein-protein interactions among risk genes. Here, established network-based methods were used to characterize the biological relatedness of schizophrenia and cognition by examining the genetic link between schizophrenia risk genes and genes associated with cognitive performance in healthy individuals, through the protein interactome. First, network separation showed a profound interactome overlap between schizophrenia risk genes and genes associated with cognitive performance (SAB = -0.22, z-score = -6.80, p = 5.38e-12). To characterize this overlap, network propagation was thereafter used to identify schizophrenia risk genes that are close to cognition-associated genes in the interactome network space (n = 140, of which 54 were part of the direct genetic overlap). Schizophrenia risk genes close to cognition were enriched for pathways including long-term potentiation and Alzheimer's disease, and included genes with a role in neurotransmitter systems important for cognitive functioning, such as glutamate and dopamine. These results pinpoint a subset of schizophrenia risk genes that are of particular interest for further examination in schizophrenia patient groups, of which some are druggable genes with potential as candidate targets for cognitive enhancing drugs.